Form 4: Catalyst Pharmaceuticals CEO Richard Daly Reports Stock Transactions
SEC Form 4 Filing
Richard Daly, CEO of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On January 2, 2025, Richard Daly, the President and CEO of Catalyst Pharmaceuticals, had 42,105 restricted stock units vest.
- Following the vesting, 10,600 shares were withheld by the company to cover applicable withholding taxes.
- After these transactions, Daly directly owns 267,338 shares of Catalyst Pharmaceuticals common stock.
- Daly also directly owns 2,238,753 derivative securities in the form of restricted stock units.
- The restricted stock units vest in equal tranches annually from January 1, 2025, to January 1, 2029.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation. It doesn't indicate any significant positive or negative sentiment.
Future Outlook
The remaining restricted stock units will continue to vest in equal tranches on January 1st of each year from 2026 to 2029.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the CEO's compensation structure includes stock-based awards.
Stakeholder Impact
- The vesting of restricted stock units has a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of transaction: Vesting of restricted stock units and tax withholding. |
| 01/03/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.